Compare Cassava Sciences Inc (FLNA) vs SAP SE (SAP) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

SAP trades at $210.13, down slightly by 0.16% on the day. The stock shows strong fundamentals with 2025 revenue of $36.80 billion and net income of $7.16 billion, yielding a net margin of 20.41%. Recent earnings beat estimates in Q4 2025 and Q1 2026 but missed in Q2 2026. Technical indicators are bullish on moving averages, with support near $209 and resistance at $213. Analyst consensus is a buy with a $253.40 price target, implying significant upside.

Outlook remains positive driven by cloud revenue growth and AI integration, though risks include competitive pressures and execution challenges. The stock offers value with a P/E of 28.26, below the software sector average, and robust cash flow generation supports shareholder returns via buybacks.